Latest Conference

Gerald Maguire, MD, discusses the unmet needs of patients with comorbid ADHD and stuttering.

Tim Wilens, MD, discussed mechanism of action and efficacy of new medications at APSARD Conference.

From APSARD 2026, a patient journey demonstrates opportunities in psychiatric education on stuttering and emerging treatment approaches.

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Review the misperceptions patients and clinicians may have about ADHD diagnosis and treatment.

Experts discuss the complex relationship between ADHD treatment and substance use disorder.

Barry Herman, MD, shares insights on real-world data of online ADHD assessment tool and telepsychiatry.

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

A groundbreaking online ADHD assessment shows 78% agreement with clinician evaluations, enhancing access to mental health care for adults.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Poster discusses evidence-based strategies for managing adult ADHD, including medication guidelines and considerations for comorbid conditions.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

A look at upcoming presentations at APSARD 2026, January 15-18.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

New neuroimaging data reveals XPro1595's potential to combat neuroinflammation in early Alzheimer’s disease, offering hope for slowing progression.

Experts discuss the significant impact of tardive dyskinesia, emphasizing the need for better recognition and treatment strategies in patient care.

What is the neuroplasticity hypothesis and why is it more important now than ever?

Discover insights on bipolar disorder diagnosis and treatment challenges, emphasizing the importance of accurate assessment for effective care.

The language clinicians use while talking to postpartum patients is critical. Learn more on best practices in treating this unique patient population.